Clinical trial
STREAM: A Phase 1/2, Open-label, Safety, Tolerability and Preliminary Efficacy Study of Implantation Into One Eye of hESC-derived RPE in Patients With Retinitis Pigmentosa Due to Monogenic Mutation
NCT03963154 is registered in ClinicalTrials.gov with Centre d'Etude des Cellules Souches as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- STREAM: A Phase 1/2, Open-label, Safety, Tolerability and Preliminary Efficacy Study of Implantation Into One Eye of hESC-derived RPE in Patients With Retinitis Pigmentosa Due to Monogenic Mutation
- Lead sponsor
- Centre d'Etude des Cellules Souches
- Phase
- Phase 1/2
- Overall status
- Active, not recruiting
- Start date
- August 19, 2019
- Completion date
- December 15, 2026
- Enrollment
- 7 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.